Rhinovirus viral capsid protein VP0 (HRV VP0)

The Rhinovirus viral capsid protein VP0 is a critical structural precursor found in Human Rhinoviruses (HRV), the primary causative agents of the common cold. During the final stages of virion maturation, VP0 undergoes an autocatalytic cleavage into two smaller proteins, VP2 and VP4, a step that is essential for the virus to become infectious (Source: UniProt, P03303; PubMed: 11967305). The resulting capsid, composed of VP1, VP2, VP3, and VP4, protects the viral RNA genome and facilitates entry into host cells by binding to receptors such as ICAM-1 or the low-density lipoprotein receptor (Source: NIH, StatPearls). In drug development, the capsid is a major therapeutic target for 'capsid binders' like pleconaril, which integrate into a hydrophobic pocket within the capsid structure to prevent the 'uncoating' process required for the virus to release its genetic material (Source: PubChem, CID 10230). Furthermore, the VP0 protein and the overall capsid surface are primary targets for the development of neutralizing antibodies and vaccines aimed at preventing HRV-induced respiratory complications, such as asthma and COPD exacerbations (Source: Journal of Virology, doi:10.1128/JVI.01704-16). Despite its potential, the significant genetic diversity among rhinovirus serotypes remains a major challenge for achieving broad-spectrum efficacy.

Other names

VP0 precursor proteinRhinovirus capsidVP4-VP2 complexPicornavirus VP0Capsid protein VP0

Capsid stabilization to prevent viral uncoating and genome release; blocking of viral attachment to host cell receptors.